Published in Transl Res on October 14, 2009
Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother (2014) 0.78
Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther (2015) 0.78
Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis? Transl Res (2009) 0.75
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J (2003) 1.90
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res (2002) 1.73
Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood (2013) 1.69
Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin: further support for existence of a new zinc overload syndrome. Arch Neurol (2003) 1.57
XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell (2006) 1.50
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol (2006) 1.43
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res (2003) 1.40
CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas (2007) 1.39
Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res (2006) 1.34
A cross-sectional study of risk factors for musculoskeletal symptoms in the workplace using data from the General Social Survey (GSS). J Occup Environ Med (2007) 1.22
Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl (2002) 1.14
Copper toxicity in the general population. Clin Neurophysiol (2010) 1.12
Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res (2010) 1.05
Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med (2003) 1.05
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res (2014) 1.05
Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology (2006) 1.05
Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology (2009) 1.04
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg (2008) 1.04
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther (2003) 1.03
The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark (2008) 1.01
Comparison of imputation methods for missing laboratory data in medicine. BMJ Open (2013) 1.01
Control of copper status for cancer therapy. Curr Cancer Drug Targets (2005) 0.99
Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res (2009) 0.98
Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol (2003) 0.96
Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia (2002) 0.96
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs (2008) 0.93
Rediscovery of the susceptibility of G6PD deficient persons to methemoglobinemia from oxidant drugs, and to hemolysis from methylene blue. Am J Hematol (2007) 0.91
Visual contrast sensitivity testing: a comparison of two F.A.C.T. test types. Neurotoxicol Teratol (2004) 0.89
Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. Int J Infect Dis (2003) 0.88
Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci (2011) 0.88
Trends in work-related musculoskeletal disorders: a comparison of risk factors for symptoms using quality of work life data from the 2002 and 2006 general social survey. J Occup Environ Med (2011) 0.88
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark (2012) 0.88
Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med (2005) 0.87
Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res (2014) 0.86
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia (2002) 0.86
Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci (2005) 0.85
Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther (2008) 0.85
Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology (2017) 0.83
Toxicity of copper in drinking water. J Toxicol Environ Health B Crit Rev (2010) 0.83
Funding anatomic pathology research: a retrospective analysis of an intramural funding mechanism. Arch Pathol Lab Med (2013) 0.82
White matter changes in Wilson disease. Arch Neurol (2002) 0.82
Autonomic dysfunction in Wilson's disease. Clin Auton Res (2002) 0.81
A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables. BMC Med Genomics (2013) 0.81
Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg (2003) 0.81
Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models. Transl Res (2006) 0.79
Tetrathiomolybdate therapy protects against concanavalin a and carbon tetrachloride hepatic damage in mice. Exp Biol Med (Maywood) (2004) 0.79
Gastritis cystica profunda versus invasive adenocarcinoma. Am J Surg Pathol (2012) 0.79
Atypical childhood Wilson's disease. Pediatr Neurol (2004) 0.79
Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection. PLoS One (2013) 0.79
The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem (2006) 0.79
Improved biomarker performance for the detection of hepatocellular carcinoma by inclusion of clinical parameters. Proceedings (IEEE Int Conf Bioinformatics Biomed) (2012) 0.78
Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res (2008) 0.78
Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate. Exp Biol Med (Maywood) (2009) 0.77
Divalent Copper as a Major Triggering Agent in Alzheimer's Disease. J Alzheimers Dis (2015) 0.77
Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol (2006) 0.77
Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol (2002) 0.76
Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate. Transl Res (2007) 0.76
Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord (2011) 0.76
Copper status in Alzheimer's disease and other neurodegenerative disorders: genetics, mechanisms, neurophysiology, and therapies. Int J Alzheimers Dis (2011) 0.76
Causes and diagnosis of copper deficiency. Am J Hematol (2008) 0.75
Comment on: "High concentration of zinc in sub-retinal pigment epithelial deposits" (Lengyel et al.) (Exp. Eye Res. 772-780, 84/4, 2007). Exp Eye Res (2008) 0.75
Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease. Neurosci Lett (2009) 0.75
Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc (2002) 0.75
Tetrathiomolybdate is partially protective against hyperglycemia in rodent models of diabetes. Exp Biol Med (Maywood) (2008) 0.75